Loading...

Bio-Gene Technology Limited

BGT.AXASX
Healthcare
Biotechnology
$0.03
$0.00(0.00%)
Australian Market is Open • 13:38

Bio-Gene Technology Limited (BGT.AX) Stock Competitors & Peer Comparison

See (BGT.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BGT.AXA$0.03+0.00%8.5M-2.80-A$0.01N/A
CSL.AXA$97.46+1.29%47.3B11.44A$8.63+4.32%
TLX.AXA$14.10-1.12%4.8B-473.67-A$0.03N/A
MSB.AXA$2.02-1.23%2.6B-20.40-A$0.10N/A
NEU.AXA$12.47+0.93%1.6B54.91A$0.23N/A
CU6.AXA$2.52-3.27%993.9M-9.54-A$0.28N/A
OPT.AXA$0.60+0.00%820.8M-1.40-A$0.43N/A
PYC.AXA$1.29-2.49%769.6M-16.50-A$0.08N/A
RAC.AXA$2.50-4.21%462.1M-49.40-A$0.05N/A
CUV.AXA$9.10-0.33%461.3M14.30A$0.64+0.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BGT.AX vs CSL.AX Comparison May 2026

BGT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGT.AX stands at 8.5M. In comparison, CSL.AX has a market cap of 47.3B. Regarding current trading prices, BGT.AX is priced at A$0.03, while CSL.AX trades at A$97.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGT.AX currently has a P/E ratio of -2.80, whereas CSL.AX's P/E ratio is 11.44. In terms of profitability, BGT.AX's ROE is -1.40%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, BGT.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BGT.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions